SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – ...

PAD symptoms often manifest in the feet due to fatty deposits like cholesterol building up in the arteries. The British Heart ...

Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 ...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal ...

PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the ...

Per- and polyfluoroalkyl substances (PFAS) are ubiquitous, accumulate in the environment and are difficult to break down. They are known as "forever chemicals". PFAS can compromise the immune system ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas ...